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Abstract
This paper illustrates the application of mobile and
wireless technologies for estimating the severity of
Parkinson Disease symptoms, and performing a
personalized drug administration to PD patients. The
measurements of patient finger pressures on the screen
of a smart phone, translated into analogue voltage and
digital bits, are taken by an Android App. The
computations performed through Fast Fourier
Transformations (FFT) and Reaction and Movement
time, enable the calculation of the severity of the PD
symptoms, which results in an appropriate drug
administration for that patient, at the moment when the
measurement of patient finger pressures is taken. The
novelty of this research is twofold. It allows a high level
of personalization in PD treatment and uses modern
technologies to bring new solutions in the field of drug
administration to PD patients.

1. Introduction
The problem of drug administration for patients
suffering from Parkinson’s Disease (PD) has been
known for decades and it has remained unresolved for
many reasons. Firstly, successful treatments of PD
symptoms depend heavily on a particular patient and
his/her manifestation of PD symptoms, which is often
associated with the individual experience a patient may
have throughout the day. This means that we should
personalize PD drug administration, in order to alleviate
PD symptoms a patient may have at a particular
moment. However, the personalization of medicine is
still in its infancy. Its research currently focuses more
on genome sequencing in order to learn how to group
patients based on risk of disease, or response to therapy,
or use diagnostic tests or techniques for each patient [1].
Secondly, we expect modern healthcare delivery to be
supported by smart phones and numerous Apps we run
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on them. PD patients expect and possibly require, a new
generation of hardware and software solutions in order
to address their most urgent problem, which is
personalized drug administration. Therefore in the
second decade of the 21st century we have an
opportunity to look at new ways of resolving the
problem of optimal treatments of PD symptoms using
new technologies, which may bring new solutions to old
problems. If we focus solely on the PD drug
administration, then we should find a method of
(a) collecting information about PD symptoms a
patient may have at any moment throughout the day
(b) advising the patient on the best possible drug
administration at that moment when the information is
collected.
Therefore, PD drug administration will vary from
one moment to another throughout the day, because PD
symptoms change. We should create a synergy of
hardware and software solutions for performing (a) and
(b), which enables the manipulation of sensor generated
data, as the result of the measurements of the severity of
PD symptoms. They are essential for appropriate drug
administration. Creating an App which administers PD
drugs, runs on patient smart phones, at the time when
the measurement of the severity of PD symptoms is
taken, would be the ultimate answer expected by PD
patients and healthcare professionals.
This paper is organized as follows. In the next
section we describe related work, and in section 3 we
give a background of this research and explain the
problems of PD drug administration. In section 4 we
introduce prerequisite for developing
• ParMes device, attached to a patient smart phone
which can measure the severity of PD symptoms,
• ParMesApp, an Android App, which takes these
measurements and administers drugs accordingly.
These prerequisite include the way PD symptoms are
estimated and drug administration calculated. In section
5 we explain the development of ParMes and
ParMesApp, and evaluate our solution in the
Conclusion.
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2. Related Work
At the time of writing this paper, we could not find
any published work, which either personalizes PD drug
administration through the measurement of the severity
of PD symptoms, or offers a Software Architectural
(SA) model for an App, which can advise on the best
possible drug administration for a particular patient.
Therefore we look at research in the field of remote
patient monitoring and assisted living. One of the best
sources, which compiles projects funded by the EU, is
available at [2]. They focus on e-health [3] which
changes the way we deliver health services and create
modern healthcare environments. However, in [2] the
authors divide e-health into comfort and security,
rehabilitation and chronic disease telemonitoring. Our
work should belong to the latter, because any persistent
data generated within ParMesApp can be remotely
accessed by any other e-health system and healthcare
professionals. The comparative study from [2] pushes
forward the problems, which have not been resolved yet,
such as security in, impact of cognitive science on, and
the existence of universal e-health systems.
The rapid changes and advances of mobile and
wireless technologies, which have seriously impacted
our everyday lives, have also infiltrated in healthcare
[4,5,6,7]. We have witnessed the proliferation of
wearable medical systems which have been paving the
way towards pervasive and personalized healthcare
[8,9,10,11,12,13].
PD has also attracted the attention of various
research groups in the domain of tele-monitoring and ehealth. There are numerous reports and peer reviewed
papers which range from focusing on the optimization
of symptomatic therapy for PD patients [14], techniques
for diagnosing and monitoring PD patients [15] and
projects which focus on wireless body area networks
[16] to accurate telemonitoring of PD patients through
speech tests [17], and medical devices which can be
used in the managing and understanding degenerative
diseases.
In terms of addressing the optimisation of PD
treatment, we can find various approaches which range
from the Tauberian approach [18], decision support
tools for optimal PD drug administration as in [19], to
“patient diaries”, deep brain stimulation, and combining
them with measuring/assessing levodopa-induced
dyskinesia and bradykinesia in parkinsonian disorders
[20,21].
The papers, which come slightly closer to our area
of interest, study tremor frequency [22], measure
rigidity of muscles [23], develop a quantitative method
for 3D measurement of PD tremor, measure finger
tapping contact force for quantitative diagnosis of PD,
measure maximum pinching force to evaluate

bradykinesia [24] and use single movement sensors for
motor state detection and dyskinesia [25]. When looking
at wearable sensors and systems for rehabilitation
[26,27] we can find works which use motion analysis
[28] and lateral belt worn accelerometer [29].
The field of healthcare Apps designed for helping
PD patients has been very poorly researched. We could
find publications which monitor well-being through
Apps [30], performing non invasive blood pressure
measurement with Android phones, but there are no peer
reviewed papers which focus solely on PD. The only
publication which promotes a smart phone application
for the detection of tremor is available at [31]. This
application does not administer PD drugs.

3. The Background: PD and Drug
Administration
PD is a degenerative disorder of the central nervous
system [32,33,34]. It is a chronic and progressive
movement disorder, with symptoms which worsen over
time. Most common motor signs of PD are tremor,
rigidity, bradykinesia and postural instability. Tremor
usually occurs when a limb starts slightly shaking or
oscillating with frequency 3-8 Hz [35]. Bradykinesia, or
slow movement, is manifested when patients cannot
perform fine tasks, they lose spontaneous movements
and have difficulties with facial expressions [36].
Rigidity of muscles is common, uncomfortable and
painful [37]. When the PD progresses, symptoms
become more prevalent and increase the disability of
patients.
PD is connected with death of nerve cells in
substantia nigra, as a consequence of low production of
dopamine and presence of Lewy bodies in remaining
neurons. Lewy bodies are abnormal aggregates of
protein that develop inside nerve cells and appear as
spherical masses that displace other cell components
[38]. Dopamine is a chemical that sends a message to
the part of the brain for coordination and movement.
When production of the dopamine drops below 80%,
doctors talk about PD and with over time, dopamine
doesn't stop decreasing [39].
There is no cure for PD, but there are treatments
which may alleviate the symptoms. The most frequently
used is dopamine treatments [21], which replace
missing dopamine with drugs such as Levodopa [40].
However, side effects are serious.
PD patients
experience dyskinesia or involuntary movements,
vomiting, dizziness and hallucinations [39,21]. The
severity of dyskinesia is related to the level of PD drug
administration. When PD progresses and side effects of
taking Levodopa become more severe, doctors choose
Deep Brain Stimulation [41].
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3.1. The Problem with PD Drug Administration
Optimization of PD treatment occurs when PD
patients are administered the correct drug dosage, which
suppress all symptoms, does not generate side effects
and improve patient's wellbeing.
However, PD
symptoms vary from patient to patient, they depend on
patient’s activities and may change significantly
throughout the day. It is extremely difficult to predict
the exact drug dosage for any PD patient. They are often
prescribed the same amount of drugs regardless of the
current state of their symptoms [42]. This approach of
suppressing PD symptoms develops side effects quicker
and the treatment becomes ineffective [43, 44]. The risk
of dyskinesia is constant and depends on age, progress
and severity of PD, dosage of drugs and the duration of
Levodopa treatment.
In order to extend dopamine treatment and reduce
Levodopa’s side effects, many studies have been carried
out towards the optimization of dosage of PD drugs. The
amount of dopamine in the blood and PD state have
negative correlation [22], which means the higher the
state of PD, less dopamine is produced. In order to
decrease PD’s symptoms and increase the level of
dopamine, with correct drug administration, scientists
tried two different approaches. One is based on
mathematical models for the drug administration [45]
and the other on the tracking the progress of PD
symptoms through patient diaries.
PD treatments based on patient diaries [46] initially
showed promising results. They help, if a patient keeps
his or her diary up to date. Doctors with diary's data may
set up appropriate drug administration, change settings
of the diaries [47,48] and may prescribe treatments
which will not bring new disabilities in PD patient's life.
However, the drawback of this approach is well known.
Doctors often find incomplete and constantly missing
data in patient diaries, which often makes the
optimisation of drug treatments unfeasible [49].
Administering drugs through predictions based on
mathematical models, such as the Tauberan approach
[18] or transfer function of second order [14], is based
on the level of the concentration of the prescribed drug
in the blood. However, PD symptoms vary from patient
to patient and in this approach the specificity of PD
symptoms, and ultimately personalisation of the drug
administration are lost: all patients, with a particular
level of the drug in the blood get the same dosage of
medication, regardless of the severity of their PD
symptoms.
Currently, there are no solutions which personalise
PD treatments. In other words, there are no methods
which can calculate the exact dosage for a particular PD
patient at any time during the day.

In this research, we aim to address both: how to
perform PD drug administration more efficiently and
how to personalise it according to a particular patient’s
needs. Therefore the proposal is to build a device which
can measure the status of tremor and bradykinesia in a
PD patient and generate a software program which can
calculate the most appropriate PD drug dosage for the
patient. The solutions are in creating both: a device,
equipped with sensors for the purpose of measuring PD
symptoms and a software program, which manipulates
sensor generated data in order to administer PD drugs.
Our proposed solution is described in the following
three sections.

4. Prerequisite for Developing ParMes and
ParMesApp
We developed a ParMes device for measuring the
severity of PD symptoms and ParMesApps Android
App, which takes these measurements and calculates the
best possible drug administration for a PD patient at the
time when the measurements were taken. However,
before we introduce both of them, we have to give a
more detailed explanation on how the severity of PD
symptoms can be estimated through ParMes and drug
administration calculated, based on these estimates. In
other words, understanding the role of estimation of
tremor and bradykinesia, helps in explaining the design
principles for creating both ParMess and ParMessApp.

4.1. Estimating Symptoms of PD
The severity of tremor and bradykinesia can be
estimated by measuring the applied force on the screen
of a smart phone. These two symptoms are visible on
patient hands.
The level of dopamine and tremor frequency are in
negative correlation [22]. When a patient has a low
dopamine level, the power of tremor will be higher. The
tremor's frequency occurs between 4-8 Hz. From
obtained measures, which were taken for time period T
and with sample frequency 256 Hz, our software
solution (ParMesApp) should calculate the Power
Spectrum Density (PSD) [50] for every frequency in
band pass between 4-8 Hz, and normalize these values.
Bradykinesia is measured with the help of applied
pressure on the smart phone screen. From the obtained
measurements, ParMesApp extracts reaction and
movement time [24,14] and finds the highest value of
applied pressure. Based on this value it calculates the:
• Reaction time (Eq. (1)) is measured as the time
when stimulus changes its state and measured
signal will reach threshold point which is 10% of
the measured sample with the highest value.
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•

Movement time (Eq. (2)) is measured as the time
between the end of reaction time and when signal
passes threshold 90% of the measured sample with
highest value.
If we have kn (nth sample), k10% (sample at 10% of
maximum measured value), k90% (sample at 90% of
maximum measured value), ∆t (time between two
samples (∆ = 1 ) and MMV - Maximum Measured
Value, we can then define:
tr = k10% × Δt
tm = (k90% × Δt) - tr

(1)
(2)

4.2. Calculating Drug Administration

(1 +

1)(1 +

2)

(3)

However, K, T1, T2 values were determined by
measuring medicine concentration in blood, several
times after the patient with PD was administrated
125mg of Levodopa. Because the benefits pf taking
Levodopa appears 10-15 minutes after its
administration, the authors of [14] added another
variable in order to transfer function of the second order
where t is delay time. Therefore formula (4)
replaces formula (3).
( )=

(1 +

1)(1 +

2)

+

"

(5)

In order to reduce cost function F, we have to
decrease
or increase T.
is an impulse which
determines
the
relation
between
medicine
administration and plasma level in the blood and it is a
response of a transfer function second-order system with
time leg. The amplitude of the impulse is the amount of
prescribed medicine. If we know the first applied
dosage, which initiated the system, amplitude of
impulse is the amount of the second dosage, the time
response of the system will be:
Y(t) = 40.89×δ×(e-1.67(T-0.24) – e-18.57(T-0.27))

Even mathematics is used for the optimization of
Levodopa treatment. In the pharmaceutical industry,
producers of Levodopa developed the transfer function
of the second order with drug administration as input.
The output is the concentration Levodopa in blood, as
given in [14]:
( )=

(∆, ) = ! ×

(4)

This equation models pharmacodynamics of the
drug and describes the relation of administrated drug
and effect of the drug, i.e. its amount in the blood.
Doctors predict that 1500mg/L of the medicine in the
blood is enough to suppress PD symptoms [52]. The
level of medicine in the blood and the severity of the PD
symptoms are in negative linear coloration and therefore
we can calculate the difference between the current and
desired amount of Levodopa in the blood. With this
difference we can determine the required dosage of
medicine, which won't harm the patient and will
suppress symptoms.
The cost function of medicine usage is a solution for
reducing the amount of administered medicine, where
presents dosage of the medicine and T time between two
sessions of drug administrations [51]:

(6)

However, however successful formulas (3)-(6) are,
they do not take into account that PD patients have
changeable need for Levodopa administration
throughout the day. In other words we had to create a
new formula because in our research we are interested
in the amount of prescribe at any time in the day. From
equation (6) we extracted and our final formula for
administration of drug changes into;
=

/( )
40.89 × (

0.12(

3.45)

−

07.82(

3.42)

(7)

T is determined as time between previous and
current administration of the drug, while Y(t) is the
desired level of drug in the blood, based on the ratio of
a symptom’s severity of a PD patient and a healthy
person in the same measurement range.
To summarise, we measure tremor and bradykinesia
though the following:
Tremor: if the affected limb oscillates with a
frequency between 4-8 Hz we estimate the severity of
tremor on average PSD in bandpass from 4-8 Hz. The
ratio is calculated from the average PSD of a PD patient
and a healthy person and the desired level of drug in
blood can be calculated as:
Yt(t) = 1500mg/L × (avrPSDPD patient /
avrPSDhealty person )

(8)

Bradykinesia: the desired level of drug in the blood
for patients with Bradykinesia is calculated upon
reaction and movement time. We summarised reaction
(Eq. 1) and movement (Eq. 2) time of a PD patient and
a healthy person. Based on summation and ratio
between summation, we calculated the desired level of
drug as:
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Yt(t) = 1500mg/L ×
((reaction+movement time)PD patient
/(reaction+movement time)healty person )

(9)

Picture 1 shows the PCD hardware design of ParMes
and Figure 2 shows how its device is attached to a smart
phone.

5. ParMes Device
The main purpose of ParMes is to measure applied
pressure of a human finger on its screen.
For creating ParMes we had two options. We could
either attach ParMes on the back of a smart phone, in
which case ParMes becomes a ”slave”, or create a
completely new device which would not need a smart
phone and would perform all: measurements, drug
dosage calculation and interaction with a PD patient.
Option 1 allows the use of parts and existing
functionalities of smart phones and takes advantage of
numerous software solutions, which exist on smart
phones, in order to perform computations and ultimately
deliver services expected by a PD patient.
Option 2 would require more resources in order to
deliver both: creation of hardware parts for ParMes
(including screens) and software components. This
option can not offer as attractive operating environments
for software development as our smart phones do.
We chose option 1 and “the screen”, which we refer
to is the screen of a smart phone. Our ParMes should
behave as a slave device. When ParMes receives a
request to measure a pressure caused by a PD patient’s
finger, it starts measuring the applied force on the screen
and sends the results of the measuring to the smart
phone.
Therefore, smart phones manipulate the
measurements of pressure caused by a human finger.
There were two important issues which had to be
addressed before ParMes was designed.
Firstly, we had to take into account that the time
between the beginning and the end of the measurement
of a pressure, caused by a human finger, with ParMes is
10 seconds. In this period ParMes sends 256 samples of
applied force per second.
Secondly, we had to design hardware, which will
meet special requirements. It is supposed to be small
and convenient to use.
ParMes includes some basic analogue components
such as an operational amplifier, switches and elements
with resistive and capacitive properties and digital
logical operators such as AND, OR, NOR, NAND,
XOR, MUX and D-FlipFlops. They will naturally
convert into electrical circuits. Therefore ParMes has
Analogue part, which measures voltage resulting after
applying finger pressure and Digital part, which
transforms these measurements into digital streams.

Figure 1. PCB hardware design of ParMes

Figure 2. ParMes device attached on smart phone

6. ParMesApp Android Application
The design and development of the ParMesApp have
three prerequisites.
Firstly, an overall SA was needed for creating an
environment where ParMesApp can reside and use
sensor generated data by ParMes. The SA must also
accommodate the functionality, which is expected to be
delivered through the ParMesApp. However, in this
highly interactive and mobile environment, User
Interfaces (UI) usually govern the logic of the
manipulation of ParMesApp by a particular PD patient.
Consequently, the functionalities depicted in the SA
must be accompanied by a set of UI, which illustrate the
way our ParMesApp works and the way a PD patient
may manipulate it. The UI for our ParMesApp is given
in Figure 3.
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Secondly, the abstract model of the SA, must be
created through either UML diagrams or software
patterns like Model-View-Controller (MVC) [52]. It
should be layered and component based. It should also
deliver a generic solution for the manipulation of sensor
generated data from ParMes and consequently absorb or
accommodate all possible changes we may have in
future when using ParMesApp. The SA should also
accommodate the way the calculations of Tremor/
Bradykinesia/PD drug administration are performed: we
should be able to change the code for calculations and
algorithms in future, if required.
Thirdly, software components defined through the
ParMesApp SA must be deployable within the Android
Integrated Development Environment (IDE), such as
Android Studio. Therefore, abstract SA components
become technology specific in order to have a
successful deployment of ParMesApp. It is assumed,
particularly if MVC pattern is used, that SA strictly
distinguishes between UI defined at the front end of
ParMesApp and repositories of data, generated by
sensors within ParMes, which are used for calculating
drug administration for PD patients.
Figure 3 shows UIs for ParMessApp. In the first UI,
only two buttons are available: “TREMOR” and
“BRADYKINESIA”. When a PD patient chooses which
type of measurement he/she needs, the ParMesApp will
lead the patient through the measurement procedure.
When the measurement is completed, ParMesApp will
show the results which are expected to be “Severity of
PD
symptoms”
and
“Recommended
drug
administration”. The result screens are visible in the
lower part of Figure 3.
Figure 4. is a generic, layered and component based
SA model for ParMesApp. It uses the Model-ViewController (MVC) pattern. This model is deployable in
many component based operating environments which
are underpinned with component technologies [53,54].
Android IDE uses plug-ins which deploy the
architectural solution from Figure 4. within the Android
Studio.
In Figure 4, UIs, which are illustrated in Figure 3,
are in boxes with yellow borders. Computation which
control the ParMesApp are in red, calculations of drug
dosage (named FFT and R&M) are in green and data
repositories are in blue. A strict division between UI,
computations and data is essential. This makes the SA
solution from Figure 4 reusable in any other IDE.
ParMesApp may have two different types of
repositories. One should be a pool of sensor-generated
data (SGD) by ParMes, which contains measurement of
a PD patient's finger pressure. This data does not have
to be persistent. SGD belong to a particular moment of
measurement and cannot be used again for a new
calculation of the drug dosage. The other type of data is

a traditional database repository, i.e. persistent data,
which may store demographic and clinical data relevant
to a particular PD patient. The development of the latter
is outside the scope of this paper. However, access to
persistent data must be guaranteed through the SA
offered for ParMesApp. In other words, the SA model
gives provision for accessing any persistent repository
of structured data, if needed.

Figure 3. User interfaces in ParMesApp
It is important to note that all computations in Figure
4, which need data, will be performed after retrieving
relevant data. This applies to all types of data: it can
either be sensor generated data from ParMes or
persistently stored data, about PD patients. This puts
forward the main characteristics of this SA solution: all
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components shown in Figure 4 might be located on
different nodes of any computer network. The solution
consequently allows data sharing in their repositories
and makes provisions for flexibility in case we change
the way we digitalize analogue signals of ParMes, or
change the way we calculate recommended drug
dosage. This is particularly important if advances in
research on treatments of PD would make the change
necessary.

to a smart phone and running an App on the phone, in
order to measure the rigidity of PD patient’s muscles, is
reusable in other healthcare domains. This was not
expected. Both solutions ParMes and ParmessApp will
require no major changes if we wish to use both in
different environments and for different purposes.
However, the evaluation prompted another
important aspect of ParMes, which should be debated.
While testing ParMes and analysing Apps available on
our smart phones, it became obvious that smart phones
are becoming more efficient in managing our wellbeing
and more popular in the delivery of healthcare, then
various gadgets specially designed for healthcare.
Therefore we had to ask questions: Was our PaerMes
necessary? Would we achieve the same result if we used
either Android or iOS devices and run ParMessApp on
them?
We debate these two outcomes in section 7.1 and
7.2.

7.1. Evaluation

Figure 4. Software Architecture for ParMesApp
Finally, sensor generated data may not be important
to store and keep it as historical data, i.e. it might not be
advisable to make it persistent. What is important here
is to make decision on the PD drug administration
possibly
persistent
and
encourage
frequent
measurements of Tremor and Bradykinesia in order to
minimize errors when administering PD drugs.

7. Conclusions
In this paper we demonstrate that it is feasible to
utilise modern hardware/software technologies for
creating dynamic cyber-physical environments where
PD patients are able to measure the severity of their
symptoms, at any time throughout the day, and have the
PD drugs administered according to these
measurements. ParMes and ParMesApp have been
developed as prototypes, but their commercialisation is
a small step away from the results of this research.
There are two important outcomes from this
research.
The evaluation of ParMes and ParmessApp has
revealed that the idea of creating a device, attaching it

It is important to note that connecting ParMes,
equipped with sensors which generate data, with an
Android App, which is built upon a specific SA style
from Figure 4, answers many questions we may have
when evaluating the results of this research.
Firstly, the generic SA style from Figure 4, based on
MVC pattern, secures the flexibility of the ParMesApp
because its computational components are separated
from persistence / data repositories and UI. Any future
changes we may have when estimating tremor and
bradykinesia and calculating the recommended drug
dosage can be easily accommodated within the
ParMesApp, without affecting most of its software
components.
Secondly, if we needed readings of anyone’s finger
pressure on a smart phone screen for any other condition
or illness, the SA of ParMesApp provides a clearly
defined UI and repository components which can be
developed for drug administration not related to PD. In
other words, we can use the model defined in Figure 4
for drug administration of any other condition which
may depend on the measurements of someone’s finger
pressures.
Thirdly, the SA from Figure 4 is a sound way of
creating Apps if we wish them to be robust and reliable
when they are run by patients. If the SA style defined
in Figure 4 is deployable within an Android Studio, as
an IDE, then we should be able to promote this
particular way of constructing software for pervasive
healthcare. In other words, any future App which
depends on the manipulation of sensor generated data,
should exploit the power of Figure 4 before developers

3495

start coding in Android or any other mobile /wireless
operating environments.
Finally, Our ParMesApp delivers advice on PD drug
administration at the moment when the measurement of
PD symptoms are taken. It personalizes drug
administration and makes it precise to fit the needs of a
patient, at the moment when the patient decides.
ParMesApp can run many times per day, when PD
symptoms change. This might be the most important
outcome of this research.

7.2. ParMes in Testing
Throughout the development process of ParMes and
ParMesApp we were constantly aware that our idea of
creating a separate mobile device ParMes for the
measurements of the finger pressure of a PD patient may
lead us towards a completely different debate on the
efficiency of having two mobile devices.
Our ParMes is attached to a smart phone and in
numerous testing, this synergy worked very well. We
proved that it was not difficult to design and develop
ParMes, but it was extremely difficult to place the
computations for drug administration on it. We needed
a smart phone and its operating environment, if we
wished to manipulate sensor-generated data. Smart
phones give much more power and opportunities for
creating intelligent software solutions, compared to any
device (gadet) equipped with sensors.
Consequently having a new developed gadget
ParMes as a “slave” to any Android smart phone, in
order to enable decision making on PD drug
administration, was a necessity. Patients do want to run
Apps on their own smart phones and therefore there was
no other way but to use ParMes as a slave. We could
not make conclusions on the readiness of smart phone
technologies to replace our ParMes, but the
computational intelligence we could create on ParMes
could not be compared with powerful Android, which is
present almost everywhere and across environments
where we need to run Apps.

7.3. Future Work
Considering our debate in sections 7.1. and 7.2, more
research is needed to investigate how smart phones
might replace ParMes in future. Computationally
powerful Android environments can carry sophisticated
calculations, which could question the existence of
numerous gadgets we buy off the shelf. These gadgets
assist in our everyday lives, but do not have enough of
their own power in order to create intelligent software
solutions for users.
It has to be debated if the future of pervasive
healthcare is in

(a) creating more mobile devices equipped with
sensors, and add more computational power to them or
(b) increasing the use of smart phones, instead of
developing more gadgets equipped with sensors. Smart
phones provide a window of opportunities because they
live in Android (or any other similar) operational
environments and can create naturally more intelligent
software solutions for the delivery of healthcare.
Our ParMesApp on an Android phone can
manipulate sensor-generated data and perform
relatively complicated calculations, but ParMes alone
can not do it. It remains to be seen which way gadget
manufacturers and App developers will go. Whatever
the future of ParMes would be, the reusability of SA
form Figure 4 guarantees successful creation of Apps in
any operating environment, if relevant sensor generated
data is supplied.
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